Stereotaxis, Inc. (STXS) Stock Forecast
Data as of Sep 19, 2026Healthcare · Current price $1.30 (+1.55%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
STXS vs Sector & Market
| Metric | STXS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.26 | 2.42 |
| Analyst Count | 3 | 8 | 18 |
| Target Upside | +168.5% | +22243.5% | +21.5% |
| P/E Ratio | -8.25 | 3.77 | 38.34 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $10M | $11M | $11M | 1 |
| 2026-12-31 | $11M | $12M | $12M | 2 |
| 2027-03-31 | $13M | $13M | $14M | 1 |
| 2027-06-30 | $13M | $14M | $14M | 2 |
| 2027-09-30 | $14M | $14M | $15M | 2 |
| 2027-12-31 | $14M | $15M | $15M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.05 | $-0.05 | $-0.04 | 1 |
| 2026-12-31 | $-0.04 | $-0.04 | $-0.04 | 1 |
| 2027-03-31 | $-0.03 | $-0.03 | $-0.02 | 1 |
| 2027-06-30 | $-0.03 | $-0.03 | $-0.02 | 1 |
| 2027-09-30 | $-0.02 | $-0.02 | $-0.02 | 1 |
| 2027-12-31 | $-0.02 | $-0.02 | $-0.02 | 1 |
Frequently Asked Questions
What is the analyst consensus for STXS?
The consensus among 3 analysts covering Stereotaxis, Inc. (STXS) is Buy with an average price target of $3.50.
What is the highest price target for STXS?
The highest analyst price target for STXS is $3.50.
What is the lowest price target for STXS?
The lowest analyst price target for STXS is $3.50.
How many analysts cover STXS?
3 analysts have issued ratings for Stereotaxis, Inc. in the past 12 months.
Is STXS a buy or sell right now?
Based on 3 analyst ratings, STXS has a consensus rating of Buy (2.00/5) with a +168.5% upside to the consensus target of $3.50.
What are the earnings estimates for STXS?
Analysts estimate STXS will report EPS of $-0.05 for the period ending 2026-09-30, with revenue estimated at $11M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.